Livzon Pharma Announces Updated Board and Committee Line-up

Bulletin Express
11/12

Livzon Pharmaceutical Group Inc. (Livzon Pharma) has released an updated roster of its Board of Directors and the corresponding committee assignments, effective 12 November 2026 from headquarters in Zhuhai, China.

The Board now comprises nine members: • Executive Directors – Chairman and President Liu Daping; Vice Chairman Tang Yanggang • Non-executive Directors – Lin Nanqi, Qiu Qingfeng, Zhu Linlin • Employee Representative Director – Ran Yongmei • Independent Non-executive Directors – Luo Huiyuan, Cui Lijie, Wang Zhiyao, Kang Li

Five board committees remain in place, with leadership and membership as follows: 1. Audit Committee: Chaired by Independent Non-executive Director Luo Huiyuan, with Kang Li, Cui Lijie, and Wang Zhiyao serving as members. 2. Remuneration and Assessment Committee: Chaired by Independent Non-executive Director Cui Lijie; Tang Yanggang, Kang Li, and Ran Yongmei are members. 3. Nomination Committee: Independent Non-executive Director Kang Li takes the chair; Tang Yanggang, Cui Lijie, and Ran Yongmei serve as members. 4. Strategy Committee: Chairman Liu Daping heads the committee, joined by Tang Yanggang and Cui Lijie as members. 5. Environmental, Social and Governance Committee: Chaired by Liu Daping, with Tang Yanggang and Kang Li as members.

These appointments reinforce Livzon Pharma’s governance framework by balancing executive leadership with independent oversight and specialized committee expertise.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10